Tafalgie Therapeutics,
Pain Treatment:
A New Pharmaceutical Approach
Our project
Tafalgie Therapeutics is an early-stage Biotech company focusing on the development of nextgeneration analgesics.
Tafalgie Therapeutics is a spin-off from the CNRS / Aix-Marseille University IBDM laboratory, specializing in the development of next-generation pain-relieving peptides, devoid of the disabling side effects of opioids. Based on the identification and understanding of a novel mechanism of action linked to the analgesic effect of a secreted endogenous protein TAFA4, which modulates the pain signal between the peripheral sensory neurons and the central nervous systems.
These future first-in-class analgesic peptides should be able to relieve and prevent acute and chronic pain, without loss of efficacy over time, and with a massive reduction in the side effects currently associated with most analgesics (such as anxiety, respiratory problems, dizziness…).
These peptides should clearly act as disease modifiers capable of blocking pain-initiating mechanisms.
Mission
Latest News
Values
Tafalgie’s team is brought together by a shared vision and values
Integrity:
Achieve the best level of evidence
Safety:
Reduction of Side Effects
Excellence:
Fruitful collaboration between researchers, clinicians, and industry
TOWARDS BETTER HEALTH FOR ALL
Tafalgie was founded with two guiding principles in mind:
- Ensuring the highest level of scientific proof for our molecules, regarding their efficacy, safety and all other effects
- Designing new drugs with affordability in mind, so that these next-generation analgesics are accessible to everyone
TAFALGIE IS ROOTED IN THE MARSEILLE REGION
Our ambition is to develop fruitful collaborations with the clinical and research ecosystem in Europe, and to create in Marseille a new joint center of excellence in the research and development of pain medications
